Perspective review demonstrates scalable production and clinical uses of pluripotent stem cell-derived cardiomyocytes, highlighting the need for diverse cell lines and standardized safety guidelines.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Raniga et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: